ArticleFrontiers in oncology2025
Global, regional, and national burden of liver cancer attributable to high BMI, 1990-2021, with future projections to 2040.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimizing surgical strategy for pancreatoduodenectomy: a network meta-analysis and trial sequential analysis.Journal of robotic surgery · 2026Pooled it
- miR-885-3p promotes hepatocellular carcinoma metastasis by targeting TASP1 to stabilize HIF-1α and activate hypoxia-driven angiogenic and invasive programs.Molecular biology reports · 2026Article
- Asian Burden of Liver Cancer 1990-2021 and Predictions to 2040: An Analysis of the Global Burden of Disease Study 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High body mass index (BMI) is a key metabolic risk for liver cancer, yet global assessments of its impact are limited. This study analyzes the liver cancer burden linked to high BMI from 1990 to 2021, using frontier analysis to evaluate prevention efficiency at different SDI levels and providing future predictions of the global burden up to 2040 to guide public health strategies. Method: We analyzed global burden mortality and disability rates using 2021 data, applying age-period-cohort modeling to assess the temporal dynamics of BMI-related liver cancer burden, adjusting for period and cohort effects across 204 countries and 21 regions, stratified by sex, age, and Sociodemographic Index (SDI). The analysis incorporated frontier efficiency estimates to understand the best achievable burden reduction at each SDI level and utilized a Bayesian framework for future trend predictions. Result: From 1990 to 2021, high BMI-related liver cancer deaths reached 46,200.88 worldwide, predominantly affecting men, especially ages 70-74 and 60-64 for DALYs. The disease burden varies nonlinearly with SDI, with regional disparities: Southeastern South America and Central/Eastern Europe face the highest impact, despite higher SDIs in Japan, South Korea, and Singapore, where the burden is comparatively lower. Frontier analysis reveals that countries with higher SDI levels have optimized prevention and control strategies, achieving lower burdens, while lower SDI regions still face significant challenges. The future projections indicate that the global burden of high BMI-related liver cancer will continue to rise by 2040, with rapid increases in male populations, although female predictions show more gradual growth. Conclusion: High BMI contributes to the increasing and unequal global burden of liver cancer, mainly impacting men, seniors, and middle-to-high SDI areas. Urgent, targeted efforts are needed to combat obesity, metabolic issues, and healthcare inequalities to reduce future risks. Future prevention strategies should incorporate continuous monitoring and adaptive responses to dynamic factors influencing liver cancer attributable to high BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.